HMGB1 and inflammatory bowel disease: Inflammasome-dependent mediators such as IL-1β, IL-18, and HMGB1 have been identified as potent promoters of intestinal pathology, which suggests that targeting these mediators may represent a useful therapeutic approach in inflammatory bowel disease (IBD) [40].